Titolo progetto

Merito

CV e struttura

Punteggio finale

Paroxysmal Nocturnal Hemoglobinuria related thrombosis: descending from the top of the iceberg.

16

15.8

31.8

Epigenetic alterations of the microenvironment in therapy-related myeloid neoplasms.

21

16.9

37.9

Plasmonic exosomes for enhanced monitoring of Monoclonal Gammopathy of Undetermined Significance.

13

11.8

24.8

Molecular basis and prognostication of Secondary Myelofibrosis.

24

2.9

26.9

Minimal Residual Disease detection by quantitative PCR in Mantle Cell Lymphoma: prospective evaluation of patients enrolled in a large, multicenter clinical trial.

16

11.1

27.1

Targeting hematopoietic stem cells expansion in CEBPA mutant AML.

17

13.9

30.9

Clinical and laboratory characterization of platelet dysfunction caused by Ibrutinib treatment in patients with Chronic Lymphocytic Leukemia and potential reversal by Desmopressin administration.

28

10

38

Transferrin Receptor Type 2 and Erythropoietin Receptor in myelodysplastic syndromes: two new possible prognostic indicators of response to erythropoietin and erythropoiesis stimulating agent treatments.

23

14

37

The genome of diffuse large B-cell lymphomas associated with HCV infection.

14

10.5

24.5

Elucidating the functional in vivo role of BOCR mutation in Acute Myeloid Leukemia.

18

14

32

Precise diagnosis in T-acute lymphoblastic leukemia (T-ALL). Translation of new results from research to diagnostic tests.

23

14.4

37.4

The prognostic impact of subclonal TP53 gene mutations detected by next generation sequencing in good risk chronic lymphocytic leukemia (CLL) patients.

5

9

14

The inhibition of the DNA damage response pathway using Bosutinib isomer (Bos-I) as a novel treatment for Acute Lymphoblastic Leukemia.

23

13

36

Erythroblastemia and other effects in natalizumab-treated patients.

15

10.3

25.3

Use of platelets as siRNA vectors for silencing the BCR-ABL fusion gene in chronic myeloid leukemia (CML).

27

11.3

38.3

Myc-related metabolism in Acute Myeloid Leukemia

23

10

33

Identification of Genomic Aberrations in Acute Myeloid Leukemia (AML) patients by Single Nucleotide Polymorphism Microarray (SNP) Approache.

9

12.3

21.3